Editor profile
Senior Editor, AI Healthcare
Elena Richter specializes in clinical AI applications, medical imaging algorithms, and AI-driven drug discovery. Her work investigates how machine learning improves diagnostic accuracy.
elena.richter@medtechdaily.orgElectronic health records giant Epic Systems has recently experienced a wave of senior executive departures, including President Sumit Rana and AI R&D head Seth Hain, among others. This series of personnel changes has sparked industry attention on the company's future strategy and competition in the healthcare technology talent market.
Researchers developed ALADYNOULLI, a Bayesian generative framework that jointly analyzes longitudinal electronic health records, age, and polygenic risk, identifying 21 reproducible disease features and improving disease prediction performance.
A comprehensive analysis of AI in healthcare adoption statistics for 2025-2026, covering market size, ROI, FDA clearances, and the widening gap between administrative and clinical diagnostic use.
Although smartwatch health data is becoming increasingly abundant, according to the latest survey by the American Medical Association (AMA), only 6% of doctors integrate it into their clinical workflow. Insurance reimbursement barriers, doubts about data authenticity, and difficulties in integrating with electronic health records are the main bottlenecks.
Analyze how regulatory pressure, demand explosion, and drug repurposing are reshaping R&D investment strategies and the market landscape for biopharmaceutical companies.
According to the latest survey by the ZS Impact Institute, 58% of American patients use tools like AI to research symptoms before deciding whether to seek medical care. AI is driving the transformation of the healthcare system from passive service to proactive support, but friction between patients and the system is also intensifying.
Six biomedical startups from Taiwan, led by Startup Island TAIWAN, held over 100 one-on-one business meetings with global pharmaceutical companies, investors, and research institutions at the BIO 2026 International Convention. Focusing on cutting-edge fields such as AI-assisted diagnostics, antibody therapies, and organoid platforms, this marks the continuous rise of Taiwan's international influence in the medical technology industry.
A recent survey by the ZS Impact Institute shows that 58% of American patients research their symptoms using AI or search engines before seeing a doctor, and 18% have directly used AI tools. The healthcare system is facing pressure from the transformation of patient behavior.
AbbVie acquires Apogee for nearly $11 billion, Sanofi changes leadership to address patent cliff, FDA reverses stance on gene therapy, and industry signals from BIO 2026 conference.
This week brought multiple major news in the biotechnology industry: Parabilis Medicines set a record with a $770.5 million IPO, Merck entered into a collaboration with Protillion worth up to $510 million for AI-driven drug discovery, a Lassa fever-rabies dual vaccine entered human trials, and CRISPR and mRNA delivery platforms demonstrated potential in treating cancer and Duchenne muscular dystrophy, respectively. These events reflect the accelerating convergence of capital, artificial intelligence, and gene editing technologies in medical innovation.
Medical AI is moving from single prediction to a new stage of integrating predictive and generative AI. By embedding into clinical workflows and adopting hybrid infrastructure, it helps medical institutions transform data insights into actionable clinical actions, improving patient outcomes and reducing the burden on doctors.
At the American Diabetes Association Scientific Sessions, Insulet, MiniMed, Dexcom, and Abbott showcased cutting-edge technologies including fully closed-loop insulin delivery systems, new evidence for continuous glucose monitoring, and multi-analyte sensors.
Adcentrx Therapeutics announced that its ADC drug ADRX-0405 has received IND approval from China's NMPA and will be included in Chinese clinical centers to conduct global Phase 1a/1b trials targeting advanced solid tumors, especially prostate cancer. This article analyzes the significance of this technology to the medical industry, market impact, and future outlook.
Artificial intelligence is revolutionizing decision-making in the biopharmaceutical industry. From drug discovery to clinical trials, AI not only accelerates processes but also forces companies to rethink how to integrate data, expert judgment, and governance structures. This article provides an in-depth analysis of the industry impact and future direction of this trend.
In recent HIMSS TV discussions, doctors at Samsung Medical Center emphasized that if healthcare systems position infrastructure modernization as an effort to improve the clinical experience rather than as a mere IT project, they are more likely to gain physician support and drive the adoption of new technologies. This approach is reshaping the procurement logic for Digital Health, Healthcare Technology, and AI Healthcare.
Centered on Fulcrum Therapeutics pausing its sickle cell disease candidate program, Eli Lilly’s RNA exon editing partnership with Ascidian worth up to $1.9 billion, Biohub’s update to its protein biology world model, and new progress in vaccine research, this article analyzes AI Healthcare, Biotech Innovation, and future capital flows from the perspective of the medtech industry.
Amgen is making additional investments in Puerto Rico to expand its biologics manufacturing network, while BioNTech is shutting down some factories in Germany and Singapore and cutting jobs. The different choices made by the two companies reflect how biopharmaceutical manufacturing is shifting from pandemic-driven expansion toward supply chain resilience, capacity efficiency, and a reconfiguration of pipeline priorities.
A lawsuit in Illinois, USA, over a patient data breach shows that even when healthcare institutions outsource their systems to vendors, they still cannot avoid their core responsibility for data security. The case sends a clearer industry signal regarding compliance governance for Digital Health, AI Healthcare, and Healthcare Technology.